

**List of International Collaborative Research Projects Approved by HMSC  
during meeting held on 12<sup>th</sup> January, 2022 (through VC)**

S. No.	Details of the Project	
1.	Sentinel Surveillance for Adverse Event of Special Interest (AESI) following COVID 19 vaccination in India	
	<b>Principal Investigator</b>  Dr Anil Gurtoo  Professor Lady Hardinge Medical College, New Delhi-110001	<b>Funding/Collaborating Agency</b>  Bill & Melinda Gates Foundation (BMGF), USA  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Rs. 9,39,15,792  <b>Duration</b> 24 Months  <b>Subject area</b> Public Health
	Approved with conditions.	
2.	Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri TM) administered by the intramuscular route in participants 6-12 months of age. [INCENTIVE: QIV3-KEM]	
	<b>Principal Investigator</b>  Dr Nithya Gogtay  Professor & Head Seth G.S Medical College and K.E.M Hospital, Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  DBT under Indo-Australia Bilateral Programme  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Rs. 61,11,84,000  <b>Duration</b> 12 Months  <b>Subject area</b> Vaccine Development
	Approved subject to certain clarifications as raised by MEA. Clarifications may be sought from PI & forwarded to MEA for taking decision on file by Chairman, HMSC.	

S. No.	Details of the Project	
3.	Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri) administered by the intramuscular route in children 3-8 years old [INCENTIVE: QIV3-KEM]	
	<b>Principal Investigator</b>  Dr Nithya Gogtay  Professor & Head Seth G.S Medical College and K.E.M Hospital, Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  DBT under Indo-Australia Bilateral Programme  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 61,11,84,000 <b>Duration</b> 12 Months <b>Subject area</b> Vaccine Development
	Approved subject to certain clarifications as raised by MEA. Clarifications may be sought from PI & forwarded to MEA for taking decision on file by Chairman, HMSC.	
4.	Developing clinical high efficiency platforms for individualised treatment through integration of advanced radiation technology, quantitative imaging and molecular biology and machine learning for treatment of cervix cancer	
	<b>Principal Investigator</b>  Dr Supriya Jayant Sastri  Professor Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  Erasmus University Medical Centre, The Netherlands  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 25,695,000 (TMC, Mumbai) <b>Duration</b> 36 Months <b>Subject area</b> Oncology
	Approved.	

S. No.	Details of the Project	
5.	Phase 2 and 3 development of an Adolescent and Young Adult module for 14-39 year olds	
	<b>Principal Investigator</b>  Dr Manjunath Nookala Krishnamurthy  Professor Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  European Organisation for Research and Treatment of Cancer, Belgium  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> 25 Euros/patient <b>Duration</b> 24 Months <b>Subject area</b> Oncology
	Approved.	
6.	The effects of anaesthetic techniques on time to start of adjuvant chemotherapy, and early and late outcomes following surgery for colorectal cancer: A prospective, multicentre, international, observational, pragmatic study	
	<b>Principal Investigator</b>  Dr Jyotsna Goswami  Senior Consultant Tata Medical Center (TMC), Kolkata-700160, West Bengal	<b>Funding/Collaborating Agency</b>  European Society of Anaesthesiology, Belgium  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Nil <b>Duration</b> 36 Months <b>Subject area</b> Anaesthesia
	Approved only for 9 sites out of 11 sites, which have submitted respective IECs. Two other sites may be considered later after submission of IEC clearances.	

S. No.	Details of the Project	
7.	Screening synthetic extracellular matrix for culturing patient derived breast cancer cells: towards personalized therapy	
	<b>Principal Investigator</b>  Dr Ashok Kumar  Associate Professor All India Institute of Medical Sciences (AIIMS), Bhopal-462024, Madhya Pradesh	<b>Funding/Collaborating Agency</b>  German Academic Exchange Service, Germany/ under DST-DAAD Call  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 39,43,025 <b>Duration</b> 24 Months <b>Subject area</b> Basic Sciences
	Approved.	
8.	An international study of molar incisor hypomineralisation and its association with dental anomalies	
	<b>Principal Investigator</b>  Dr Ashima Goyal  Professor Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012	<b>Funding/Collaborating Agency</b>  Hamad Dental Center, (HMC), Qatar & the School of Clinical Dentistry, UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Nil <b>Duration</b> 18 Months <b>Subject area</b> Dental Sciences
	Approved.	

S. No.	Details of the Project	
9.	Influence of Minority and COVID-19 Stressors on HIV Risk and Access to Services among MSM and Transgender Women: A Longitudinal Observational Cohort (S3-Plus) Study in Chennai	
	<b>Principal Investigator</b>  Dr. Aleena Sebastian  Assistant Professor Centre for Sexuality and Health Research and Policy (C-SHaRP), Chennai-600101, Tamil Nadu	<b>Funding/Collaborating Agency</b>  ICMR IAVI Joint Call for Investigator Initiated Research (IIR)  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Rs. 25,19,000  <b>Duration</b> 12 Months  <b>Subject area</b> Covid 19
	Approved.	
10.	Elucidating the role of mucosal homing cell adhesion molecules in eliciting B cell associated anti-HIV and anti-SARS-CoV2 immune responses	
	<b>Principal Investigator</b>  Miss Nandini Jayant Kasarpalkar  SRF ICMR-National Institute of Research in Reproductive Health (ICMR-NIRRH), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  ICMR IAVI Joint Call for Investigator Initiated Research (IIR)  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Rs. 23,99,360  <b>Duration</b> 12 Months  <b>Subject area</b> Covid 19
	Approved.	

S. No.	Details of the Project	
11.	Sexual networks, HIV/STI prevalence and access to services amid COVID-19 pandemic for key populations in India and Kenya	
	<b>Principal Investigator</b>  Mrs. Shruta Amit Rawat  Research Manager The Humsafar Trust, Mumbai-400055, Maharashtra	<b>Funding/Collaborating Agency</b>  ICMR IAVI Joint Call for Investigator Initiated Research (IIR)  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 52,34,140 <b>Duration</b> 12 Months <b>Subject area</b> Covid 19
	Approved.	
12.	An open-label, multicenter, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild cases of COVID-19	
	<b>Principal Investigator</b>  Dr Tanica Lyngdoh  Scientist-E Indian Council of Medical Research (ICMR), New Delhi-110029	<b>Funding/Collaborating Agency</b>  ICMR under ICMR-Drugs for Neglected Diseases Initiative (DNDi), Switzerland MoU  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 174,572,325 <b>Duration</b> 12 Months <b>Subject area</b> Covid 19
	Approved for 6 sites out of 15 sites. However, the IEC clearances of remaining 9 sites and CTRI registration number should be submitted to ICMR before initiation of the study. Moreover, for increasing the sample size and for any other site, if selected/decided later on, the prior approval of HMSC would be essential.	

S. No.	Details of the Project	
13.	Women Empowerment Cancer Awareness Nexus (WE-CAN): An Implementation Research Study of Cervical Cancer Prevention through HPV Self-Sampling and Education in India	
	<b>Principal Investigator</b>  Dr. Gauravi Ashish Mishra  Associate Professor Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  ICMR-Global Alliances for Chronic Diseases (GACD) Call  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 3,07,75,471 <b>Duration</b> 60 Months <b>Subject area</b> Oncology
	Based on the satisfactory response received from MEA, the Chairperson, HMSC Approved the proposal on 23 <sup>rd</sup> December 2021. The Committee endorsed the decision.	
14.	Preventing cervical cancer in India through self sampling (PCCIS)	
	<b>Principal Investigator</b>  Dr. Gauravi Ashish Mishra  Associate Professor Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  Inter-Council Network of Provincial and Regional Councils (ICN), Global Affairs Canada  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 65,94,533 <b>Duration</b> 15 Months <b>Subject area</b> Oncology
	Based on the satisfactory response received from MEA, the Chairperson, HMSC Approved the proposal on 23 <sup>rd</sup> December 2021. The Committee endorsed the decision.	

S. No.	Details of the Project	
15.	Smartphone based application for drug adherence and risk factor modification in outpatients with coronary artery disease – an open label randomized controlled trial	
	<b>Principal Investigator</b>  Dr Santhosh Satheesh  Professor Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry-605006	<b>Funding/Collaborating Agency</b>  JIPMER Alumni Association of North America (JAANA), USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 7,42,000 <b>Duration</b> 24 Months <b>Subject area</b> Cardiovascular Diseases
	Approved.	
16.	Introduction of a clinical guideline to manage type-2 diabetes by Ayurvedic practitioners in India: intervention development and feasibility study	
	<b>Principal Investigator</b>  Prof Tuhin Kanti Biswas  Professor J. B. Roy State Ayurvedic Medical College and Hospital, Kolkata-700004, West Bengal	<b>Funding/Collaborating Agency</b>  Medical Research Council (MRC), UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 50,75,200 <b>Duration</b> 24 Months <b>Subject area</b> Diabetes
	Approved subject to inclusion of certain comments from Min. of AYUSH before initiation of the study.	



S. No.	Details of the Project	
17.	Machine learning in the determination of complete tumor response in patients with significant amount of mucin on MRI after neoadjuvant therapy	
	<b>Principal Investigator</b>  Dr Akshay Baheti  Associate Professor Tata Medical Hospital (TMH), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  Memorial Sloan Kettering Cancer Center, USA  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Nil  <b>Duration</b> 18 Months  <b>Subject area</b> Gastroenterology
	Approved.	
18.	IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum Version 1.0, 22 January 2020	
	<b>Principal Investigator</b>  Dr. Savita Namdeo Kamble  Professor B J Medical College, Pune-411001, Maharashtra	<b>Funding/Collaborating Agency</b>  National Institutes of Health (NIH), USA  <b>Date of approval</b> January 12, 2022  <b>Total budget</b> Rs. 43,54,098  <b>Duration</b> 60 Months  <b>Subject area</b> HIV
	Approved.	

S. No.	Details of the Project	
19.	Bioactive components in breast milk impact rotavirus vaccine response	
	<b>Principal Investigator</b>  Dr Sudhir Babji  Professor Christian Medical College (CMC), Vellore-632004, Tamil Nadu	<b>Funding/Collaborating Agency</b>  National Institutes of Health (NIH), USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 42,31,764 <b>Duration</b> 24 Months <b>Subject area</b> Rotavirus
	Approved.	
20.	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	
	<b>Principal Investigator</b>  Dr Badira Cheriyaalinkal Parambil  Assistant Professor Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  NRG Oncology, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 53,53,400 <b>Duration</b> 120 Months <b>Subject area</b> Oncology
	Approved. The appropriate GoI clearances should be obtained by PI for visit of foreign team members to India.	

S. No.	Details of the Project	
21.	MT2020 App - Mechanical Thrombectomy Tracking	
	<b>Principal Investigator</b>  Dr. M V Padma Srivastava  Professor & Head All India Institute of Medical Sciences (AIIMS), New Delhi-110029	<b>Funding/Collaborating Agency</b>  Society of Vascular and Interventional Neurology (SVIN), Minneapolis  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Nil <b>Duration</b> 36 Months <b>Subject area</b> Neurology
	Approved only for AIIMS, New Delhi for which IEC clearance is submitted. The IEC clearances of rest of the 14 sites should be submitted to ICMR before initiation of the study.	
22.	Exploring the content validity of the EQ-5D across cultures using standardized qualitative methods (Does EQ-5D cover the most undesirable health problems in different cultures? A study of seven countries using a mixed methods)	
	<b>Principal Investigator</b>  Dr Shankar Prinja  Associate Professor Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012	<b>Funding/Collaborating Agency</b>  The EuroQol Research Foundation, The Netherlands  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 9,97,500 <b>Duration</b> 17 Months <b>Subject area</b> Public Health
	Approved.	

S. No.	Details of the Project	
23.	ICARUS-IBD: International study of COVID-19 Antibody Response Under Sustained immune suppression in IBD	
	<b>Principal Investigator</b>  Prof Usha Dutta  Professor & Head Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012	<b>Funding/Collaborating Agency</b>  The Leona M. and Harry B. Helmsley Charitable Trust, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 25,00,000 <b>Duration</b> 18 Months <b>Subject area</b> Gastroenterology
	Approved subject to submission of an adequate/duly signed agreement on data protection & safety by all the PIs involved.	
24.	Improving Outcomes in Depression in Primary Care in Low Resource Setting	
	<b>Principal Investigator</b>  Prof Sarman Singh  Director All India Institute of Medical Sciences (AIIMS), Bhopal-462024, Madhya Pradesh	<b>Funding/Collaborating Agency</b>  The National Institute of Mental Health (NIMH), NIH, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 14,64,13,056 <b>Duration</b> 48 Months <b>Subject area</b> Mental Health
	Approved, subject to the following: i. A copy of CTRI registration number should be submitted to ICMR before initiation of the study. ii. Name of the PI of study should be communicated to HMSC as Dr. Singh has superannuated.	

S. No.	Details of the Project	
25.	Effect of Scapula Focused Interventions on Pain and Disability in Neck Pain with Mobility Deficits- A Randomized Controlled Trial	
	<b>Principal Investigator</b>  Mr Nithin Prakash  Scholar Manipal College of Health Professions, Bangalore-576104, Karnataka	<b>Funding/Collaborating Agency</b>  Tufts University, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Nil <b>Duration</b> 18 Months <b>Subject area</b> Orthopaedics
	Approved.	
26.	Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	
	<b>Principal Investigator</b>  Dr Devendra Arvind Chaukar  Professor & Head Tata Medical Center (TMC), Mumbai-400012, Maharashtra	<b>Funding/Collaborating Agency</b>  University of Birmingham, UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 58,86,300 <b>Duration</b> 18 Months <b>Subject area</b> Oncology
	Approved.	

S. No.	Details of the Project	
27.	Perinatal mental health in India: a validation and cohort study	
	<b>Principal Investigator</b>  Dr. M Thomas Kishore  Additional Professor National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore-560029, Karnataka	<b>Funding/Collaborating Agency</b>  University of Oxford, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 1,93,44,456 <b>Duration</b> 60 Months <b>Subject area</b> Mental Health
	In view of the comments of MEA, the Committee Approved the study.	
28.	ECHO Telementoring to Improve Quality Palliative Care in Underserved Areas of Zambia, Kenya, Nigeria, Ghana, South Africa and India	
	<b>Principal Investigator</b>  Dr Somnath Dey  Assistant Professor Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital (A TMC Unit), Varanasi-221005, Uttar Pradesh	<b>Funding/Collaborating Agency</b>  University of Texas, USA  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 32,11,260 <b>Duration</b> 24 Months <b>Subject area</b> Oncology
	Approved.	

S. No.	Details of the Project	
29.	Validation of the Dual-Isotope Method for measuring ileal protein digestibility	
	<b>Principal Investigator</b>  Dr Anura V Kurpad  Professor St. John's Medical College, Bengaluru-560034, Karnataka	<b>Funding/Collaborating Agency</b>  Wellcome Trust, UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 73,94,070 <b>Duration</b> 60 Months <b>Subject area</b> Nutrition
	Approved.	
30.	Genetics of Neuroendocrine Tumours	
	<b>Principal Investigator</b>  Dr.Pinaki Dutta  Assistant Professor Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012	<b>Funding/Collaborating Agency</b>  William Harvey Research Institute, UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 1,20,000 <b>Duration</b> 17 Years <b>Subject area</b> Oncology
	Based on the satisfactory response received from MEA, the Chairperson, HMSC Approved the proposal on 23 <sup>rd</sup> December 2021. The Committee endorsed the decision.	

S. No.	Details of the Project	
31.	Role Of Educational Intervention In Improving Diagnosis and Treatment Of Central Nervous System Tuberculosis– A Cluster Randomized Trial (RED---TB Trial)	
	<b>Principal Investigator</b>  Dr Divya M R  Assistant Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029	<b>Funding/Collaborating Agency</b>  World Federation of Neurology (WFN), UK  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 18,75,000 <b>Duration</b> 24 Months <b>Subject area</b> Neurology
	Approved.	
32.	Medication adherence and management of risk factors for secondary prevention of stroke using smart phone- based application: A feasibility study	
	<b>Principal Investigator</b>  Dr P N Sylaja  Professor & Head Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram-695011, Kerala	<b>Funding/Collaborating Agency</b>  World Stroke Organization, Switzerland  <b>Date of approval</b> January 12, 2022 <b>Total budget</b> Rs. 14,00,000 <b>Duration</b> 12 Months <b>Subject area</b> Neurology
	Approved. However, the IEC clearance should be submitted to ICMR before initiation of the study.	